Ciaramella Giuseppe 4
4 · Beam Therapeutics Inc. · Filed Oct 16, 2024
Insider Transaction Report
Form 4
Ciaramella Giuseppe
President
Transactions
- Exercise/Conversion
Common Stock
2024-10-14$0.67/sh+27,318$18,303→ 196,934 total - Exercise/Conversion
Common Stock
2024-10-14$7.22/sh+1,457$10,520→ 211,370 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-10-14−27,318→ 0 totalExercise: $0.67From: 2024-04-03Exp: 2028-05-08→ Comon Stock (27,318 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2024-10-14−1,457→ 0 totalExercise: $7.22Exp: 2029-05-31→ Comon Stock (1,457 underlying) - Exercise/Conversion
Common Stock
2024-10-14$4.22/sh+12,979$54,771→ 209,913 total - Sale
Common Stock
2024-10-14$26.27/sh−51,110$1,342,752→ 160,260 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-10-14−12,979→ 0 totalExercise: $4.22From: 2024-04-03Exp: 2029-02-13→ Comon Stock (12,979 underlying)
Footnotes (4)
- [F1]The stock option exercises were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024.
- [F2]The shares of Common Stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $26.00 to $26.56, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]This stock option vested as to 25% on the first anniversary of the vesting commencement date, October 1, 2019, and at a rate of 2.78% each month thereafter until the option was fully vested.